Literature DB >> 19889003

Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes.

S Mudaliar1, A R Chang, V R Aroda, E Chao, P Burke, S Baxi, K A Griver, D T O'Connor, R R Henry.   

Abstract

OBJECTIVE: To evaluate the effects of intensive insulin therapy alone or with added pioglitazone on renal salt/water balance and body fluid compartment shifts in type 2 diabetes.
METHODS: A total of 25 insulin-treated, obese patients with type 2 diabetes were randomized to pioglitazone 45 mg (n = 12) or placebo (n = 13) and treated intensively for 12-16 weeks to achieve equivalent glycaemic control. We measured total body water (TBW) and extracellular/intracellular fluid by bioimpedance analysis; plasma/RBC volume with I(131)albumin; sodium handling by fractional excretion of sodium/lithium (FeNa/FeLi) and other renal/hormonal parameters.
RESULTS: Intensification of insulin therapy and the addition of pioglitazone significantly improved glycaemia (HbA1C 7.8-7.2% and 7.6-7.1%) and increased body weight (1.7 and 4.9 kg) respectively. TBW increased 1.7 l with insulin alone (65% intracellular) and 1.6 l with added pioglitazone (75% extracellular) (p = 0.06 and 0.09 respectively). Plasma volume increased 0.2 +/- 0.1 l with insulin alone (p = 0.05) and 0.4 +/- 0.1 l with added pioglitazone (p < 0.05). Extravascular, extracellular (interstitial) fluid increased significantly and more with added pioglitazone (0.8 +/- 0.2 l, p < 0.01) than with insulin alone (0.4 +/- 0.2 l, p = ns). At steady-state, FeLi (marker of proximal-tubular sodium delivery to the distal nephron) increased significantly with added pioglitazone (12.4 +/- 1.3 to 18.0 +/- 3.2%) vs. no significant change with insulin alone (15.4 +/- 1.2 to 14.5 +/- 2.3%). There were no significant changes in the other parameters.
CONCLUSION: In intensively insulin-treated obese type 2 diabetic patients, at equivalent glycaemic control, the addition of pioglitazone causes greater weight gain, but a similar increase in body water that is mainly extracellular and interstitial compared with intracellular increase with insulin therapy alone. Pioglitazone also increases the filtered load of sodium reabsorbed at the distal nephron with no net change in FeNa.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889003     DOI: 10.1111/j.1463-1326.2009.01126.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  11 in total

1.  Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.

Authors:  Emily Borsting; Vicki Pei-Chun Cheng; Chris K Glass; Volker Vallon; Robyn Cunard
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-14

2.  Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes.

Authors:  P K Shah; S Mudaliar; A R Chang; V Aroda; M Andre; P Burke; R R Henry
Journal:  Diabetes Obes Metab       Date:  2011-06       Impact factor: 6.577

Review 3.  Neurohumoral Integration of Cardiovascular Function by the Lamina Terminalis.

Authors:  Nicole M Cancelliere; Emily A E Black; Alastair V Ferguson
Journal:  Curr Hypertens Rep       Date:  2015-12       Impact factor: 5.369

4.  Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters.

Authors:  Li Zhou; Gang Liu; Zhanjun Jia; Kevin T Yang; Ying Sun; Yutaka Kakizoe; Mi Liu; Shufeng Zhou; Ren Chen; Baoxue Yang; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2013-09-04

Review 5.  Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.

Authors:  Rimke C Vos; Mariëlle Jp van Avendonk; Hanneke Jansen; Alexander N Goudswaard; Maureen van den Donk; Kees Gorter; Anneloes Kerssen; Guy Ehm Rutten
Journal:  Cochrane Database Syst Rev       Date:  2016-09-18

Review 6.  PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty.

Authors:  Janice V Huang; Clifford R Greyson; Gregory G Schwartz
Journal:  J Lipid Res       Date:  2012-06-08       Impact factor: 5.922

7.  Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin.

Authors:  Stanley S Schwartz
Journal:  Diabetes Metab Syndr Obes       Date:  2010-07-09       Impact factor: 3.168

Review 8.  Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease.

Authors:  Sebastian Niezen; Humberto Diaz Del Castillo; Lumen A Mendez Castaner; Alessia Fornoni
Journal:  Endocrinol Diabetes Metab       Date:  2019-05-17

9.  Baseline low-density lipoprotein cholesterol predicts the hemoglobin A1c-lowering effect of dapagliflozin in Japanese patients with type 2 diabetes mellitus.

Authors:  Tomoyuki Iwasaki; Masato Yoneda
Journal:  Diabetol Int       Date:  2015-05-31

Review 10.  Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review.

Authors:  Hengameh Abdi; Fereidoun Azizi; Atieh Amouzegar
Journal:  Int J Endocrinol Metab       Date:  2018-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.